Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 11—November 2012
Research

Epidemic Myalgia in Adults Associated with Human Parechovirus Type 3 Infection, Yamagata, Japan, 2008

Katsumi MizutaComments to Author , Makoto Kuroda, Masayuki Kurimura, Yoshikazu Yahata, Tsuyoshi Sekizuka, Yoko Aoki, Tatsuya Ikeda, Chieko Abiko, Masahiro Noda, Hirokazu Kimura, Tetsuya Mizutani1, Takeo Kato, Toru Kawanami, and Tadayuki Ahiko
Author affiliations: Yamagata Prefectural Institute of Public Health, Yamagata, Japan (K. Mizuta, Y. Aoki, T. Ikeda, C. Abiko, T. Ahiko); National Institute of Infectious Diseases, Tokyo, Japan (M. Kuroda, T. Sekizuka, M. Noda, H. Kimura, T. Mizutani); Yonezawa City Hospital, Yamagata (M. Kurimura, Y. Yahata); and Yamagata University Faculty of Medicine, Yamagata (T. Kato, T. Kawanami)

Main Article

Table 1

Demographic and clinical data for 22 patients with epidemic myalgia, Yonezawa, Yamagata, Japan, June–August 2008*

Case-patient no. Age, y/sex Illness onset date Hospital visit date Clinical symptoms Laboratory test results†
 Virus isolation RT-PCR for HPeV3
 Neutralizing antibody titer against HPeV3 (d after illness onset)
CPK CRP MYO Throat swab/stool Serum
1 36/M Jun 13 Jun 17 Myalgia, weakness, fever 222 2.3↑ 66.0↑ Throat swab –, stool – Throat swab –, stool + – 16 (21), 64 (61)
2 66/F Jun 16 Jun 17 Myalgia, weakness 66 1.5↑ 26.0 ND‡ ND – 64 (58)
3 25/M Jun 20 Jun 25 Myalgia, weakness, fever, orchiodynia 201 0.8↑ 148.0↑ ND ND – 16 (6), 16 (26)
4 31/M Jun 21 Jun 24 Myalgia, weakness, fever, sore throat 239 0.5↑ 66.0↑ ND ND + <8 (3), 16 (9), 16 (27)
5 32/M Jun 22 Jun 24 Myalgia, weakness, fever, sore throat 1,334↑ 5.0↑ 138.8↑ Throat swab –, stool – Throat swab –, stool – ND ND
6 43/M Jun 24 Jun 25 Myalgia, weakness, fever, sore throat 277 2.0↑ 73.0↑ ND ND – <8 (3), 8 (6), 32 (64)
7 30/F Jun 26 Jul 2 Myalgia, weakness, fever, 581↑ 0.1 110.0↑ ND ND – 8 (6), 32 (15), 128 (71)
8 28/M Jun 29 Jul 1 Myalgia, weakness, fever, sore throat, orchiodynia 283 4.4↑ 83.0↑ Throat swab –, stool+ Throat swab +, stool+ + <8 (2,3,5,8), 8 (17), 64 (59)
9 39/F Jun 30 Jul 7 Myalgia, weakness, fever, sore throat 262↑ 0.7↑ 81.0↑ Throat swab –, stool + Throat swab +, stool + – <8 (7), 8 (11), 32 (65)
10 36/M Jul 1 Jul 4 Myalgia, weakness, fever, sore throat 693↑ 0.4↑ 230.0↑ Throat swab –, stool + Throat swab –, stool + – 8 (8), 64 (59)
11 35/M Jul 3 Jul 6 Myalgia, weakness, fever, sore throat 782↑ 1.1↑ 124.4↑ Throat swab –, stool + Throat swab –, stool + – <8 (3,4), 16 (6), 8 (22)
12 38/M Jul 3 Jul 6 Myalgia, weakness, fever, sore throat 321↑ 0.2 201.0↑ Throat swab –, stool – Throat swab –, stool – – 8 (3), 16 (4), 32 (13), 16 (57)
13 38/F Jul 4 Jul 4 Myalgia, weakness, fever, sore throat 166↑ 0.9↑ 121.6↑ Throat swab +, stool – Throat swab +, stool + – <8 (0,3,5), 16 (14), 256 (56)
14 37/F Jul 6 Jul 12 Myalgia, weakness, seizures 426↑ 0.2 253.4↑ Throat swab –, stool + Throat swab +, stool + – 8 (8), 16 (12), 32 (24), 64 (59)
15 48/M Jul 8 Jul 11 Myalgia, weakness, sore throat 1,048↑ 1.9↑ 193↑ Throat swab –, stool – Throat swab +, stool + ND ND
16 41/M Jul 9 Jul 11 Myalgia, fever, sore throat 88 6.8↑ 29 Throat swab –, stool – Throat swab –, stool – – 8 (9,63)
17 26/F Jul 11 Jul 14 Myalgia, weakness, fever, 45 0.7↑ 18 Throat swab –, stool – Throat swab –, stool – – 16 (61)
18 36/M Jul 11 Jul 14 Myalgia, weakness, fever, sore throat orchiodynia 355↑ 0.9↑ 87↑ Throat swab –, stool + Throat swab ND, stool + – 8 (12)
19 23/M Jul 17 Jul 18 Myalgia, weakness, fever, sore throat 165 1.7↑ 31 Throat swab –, stool – Throat swab ND, stool – – <8 (1)
20 34/M Jul 19 Jul 20 Myalgia, weakness, fever, 1,598↑ 0.5↑ 75.2↑ ND ND – 16 (13,24)
21 38/F Jul 31 Aug 4 Myalgia, weakness, fever, sore throat 43 5.5↑ 35 ND ND – <8 (4)
22 55/M Aug 6 Aug 6 Myalgia, weakness, fever, sore throat, orchiodynia 556↑ 4.9↑ 26.8 ND ND + <8 (1)

*Boldface indicates HPeV3 infection confirmation by virus isolation, RT-PCR, seroconversion, 4-fold increase of neutralizing antibody. HPeV3, human parechovirus type 3; RT-PCR, reverse transcription PCR; CPK, creatine phosphokinase; CRP, C-reactive protein; MYO, myoglobin; –, negative; +, positive; ND, not done.
†Arrows indicate finding above reference levels: CPK, M: 60–287 IU/L, F: 45–163 IU/L; CRP, 0–0.3 mg/dL; MYO, M 60, F 35 ng/mL.

Main Article

1Current affiliation: Tokyo University of Agriculture and Technology Research and Education Center for Prevention of Global Infectious Diseases of Animals, Tokyo, Japan.

Page created: October 15, 2012
Page updated: October 15, 2012
Page reviewed: October 15, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external